INDSWFTLTD2023-04-012023-06-30 INDSWFTLTD2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member INDSWFTLTD2023-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524652 INDSWFTLTD NOTLISTED Ind-Swift Limited Equity 2023-04-01 2024-03-31 2023-08-10 2023-07-31 INR Lakhs First quarter 16:30:00 18:30:00 2023-08-10 2023-08-10 Not applicable Single segment Pharmaceuticals 2023-04-01 2023-06-30 Unaudited Consolidated 1485360000.00 56304000.00 1541664000.00 488104000.00 137127000.00 281529000.00 183481000.00 149451000.00 67210000.00 211138000.00 1518040000.00 23624000.00 0.00 23624000.00 0.00 0.00 0.00 0.00 23624000.00 0.00 0.00 0.00 0.00 23624000.00 0.00 23624000.00 0.00 0.00 0.00 0.00 108329000.00 2 0.44 0.44 0.00 0.00 0.44 0.44 Notes- 1 The above financial results have been prepared in accordance with IND-AS prescribed under section 133 of Companies Act,2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation 2015. 2 The Consolidated Financial Results includes the financial results of the parent Company Ind Swift Ltd and the financial results of subsidiary Company Indswift India Ltd Kenya. 3 The Company’s first Wholly owned Subsidiary in Kenya “ IndSwift India Limited “ was incorporated during the Financial Year 2022-23 and it has not commenced any operations yet. 4 Exceptional/Extraordinary items for the qtr ended 31st March, 2023 includes waiver of principle and Interest on Loan for Rs.6057.87 lacs. 5 Deffered Tax Asset/Liability will be accounted for the year end. 6 The Company is exclusively in Pharmaceutical business. 7 Previous period/ year figures have been re-grouped/Re-arranged where ever necessary. 8 The above Unaudited Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 10th,Aug, 2023. Other Expenses 211138000.00 0.00 0.00